In a deal worth up to $750 million, British pharmaceutical giant GSK has agreed to license an experimental cancer immunotherapy from Chengdu-based Chimagen Biosciences, targeting multiple myeloma — a blood cancer with few durable treatment options. The arrangement is less a singular transaction than a marker of a deeper shift: the long-assumed direction of pharmaceutical innovation, flowing from West to East, has quietly begun to reverse. China's biotech sector, built on sustained investment, scientific talent, and vast patient populations, is now producing drug candidates that global giants a